NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Changes to US Hepatitis B Vaccination Recommendations for Newborns
TL;DR
Companies like Soligenix Inc. may face reduced demand as the advisory panel's vote ends the universal Hepatitis B vaccine recommendation for newborns.
The advisory panel voted to change the Hepatitis B vaccine policy from universal newborn vaccination to targeting only babies of mothers with positive test results.
This policy change prioritizes resources for newborns at highest risk, potentially improving healthcare efficiency while maintaining protection against Hepatitis B.
After 33 years, the universal Hepatitis B vaccine recommendation for newborns is ending, shifting to a targeted approach based on maternal testing.
Found this article helpful?
Share it with your network and spread the knowledge!
An advisory panel on vaccines voted to end the recommendation that all newborns receive a Hepatitis B vaccine at birth, which has existed since 1991. Instead, they now recommend that only babies whose mothers have a positive test for hepatitis B should receive the shot at birth.
The previous recommendation requiring all newborns to receive a Hepatitis B vaccine at birth has existed since 1991.
The advisory panel voted on Friday to end the universal vaccination recommendation, according to the content.
Under the new recommendation, only babies whose mothers have had a positive test for hepatitis B should receive the vaccine at birth.
The content mentions Soligenix Inc. (NASDAQ: SNGX) as a company that also has vaccine-related activities.
This content was published by BioMedWire (BMW), a specialized communications platform focused on the latest developments in Biotechnology, Biomedical Sciences, and Life Sciences sectors.
Readers can click the 'Read More' link in the content or visit the BioMedWire website at https://www.BioMedWire.com for more information.
To receive SMS alerts from BioMedWire, text 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only).
Readers can contact BioMedWire at Editor@BioMedWire.com or call 415.949.5050 Office for more information.
Curated from InvestorBrandNetwork (IBN)
